中国高阶工程师红利兑现刺激创新药产业趋势！可T+0交易的港股创新药ETF（159567）逆势上涨，实时换手率超30%排名同指数第一

Group 1 - The Hong Kong stock market experienced a significant pullback on May 30, yet the innovative drug sector saw gains, with notable increases in stocks such as CSPC Pharmaceutical rising over 8% and others like Fosun Pharma and Zai Lab increasing over 5% [1] - The Hong Kong innovative drug ETF (159567) attracted over 200 million yuan in net inflows over the past 20 trading days, indicating high market interest [1] - The development of innovative drugs in China is driven by the transformation of generic drug companies and the emergence of biotech firms, supported by unmet clinical needs and the urgency of multinational pharmaceutical companies to fill their pipelines as they approach patent cliffs [1] Group 2 - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the international expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from both AI advancements and the introduction of new healthcare policies targeting high-priced innovative drugs [2] - The investment value of domestic innovative drug companies is increasingly highlighted in the current market environment, with recent sector pullbacks attributed more to external policy expectations rather than fundamental changes [2]